Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT
Links:
Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Ar…
https://acrabstracts.org/abstract/comparisons-of-non-tnfi-biologic-and-targeted…
17-11-2024